中东和非洲前列腺癌诊断市场 – 行业趋势和 2028 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

中东和非洲前列腺癌诊断市场 – 行业趋势和 2028 年预测

  • Medical Devices
  • Published Report
  • Mar 2021
  • MEA
  • 350 页面
  • 桌子數: 123
  • 图号: 55

>中东和非洲前列腺癌诊断市场,按产品类型(仪器、试剂、耗材和配件)、诊断类型(初步筛查测试、确认测试)、年龄组(成人、儿童和老年病学)、类型(前列腺腺癌、小细胞癌等)、分期(局限性前列腺癌、复发性/晚期前列腺癌和去势抵抗性前列腺癌(转移性和非转移性))、样品类型(血液、组织、尿液等)、最终用户(独立诊断实验室、医院、癌症研究机构、诊所、门诊手术中心等)、分销渠道(直接招标、零售)、国家(南非、沙特阿拉伯、阿联酋、埃及、以色列和中东及非洲其他地区)行业趋势和预测到 2028 年     

中东和非洲前列腺癌诊断市场市场分析与洞察:中东和非洲前列腺癌诊断市场

前列腺癌诊断市场预计将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析,在 2021 年至 2028 年的预测期内,该市场的复合年增长率为 12.9%,预计到 2028 年将达到 3.204 亿美元。对疾病负担的关注度不断提高和对疾病的认识不断提高是预测期内推动前列腺癌诊断市场发展的主要驱动力。

当前列腺细胞开始以异常速度生长时,前列腺癌就开始了,这种情况被称为前列腺癌。前列腺是男性特有的腺体。它会产生精液中的部分液体。前列腺癌诊断是一种主要在早期检测癌症的技术,以便进行未来的治疗方法,从而提高存活率。

前列腺癌的发展与年龄密切相关,随着老年人口的增加,前列腺癌的发病率显著增加。这将增加对用于检测疾病的诊断产品的需求,并有望成为前列腺癌诊断市场的驱动力。PSA 检测是用于前列腺癌检测的主要检测之一。然而,政府和医疗服务提供商在使用 PSA 和相关检测方面的矛盾预计将制约前列腺癌诊断市场的发展。该市场具有巨大的增长潜力,随着新市场参与者试图通过分销协议利用业务扩张进入市场,并已投资于前列腺癌诊断,预计市场规模将扩大,并将为前列腺癌诊断市场带来机遇。与进行癌症诊断测试相关的障碍可能会影响人口的寿命,这是低收入国家最难克服的部分之一,因此这影响了诊断界,并对前列腺癌诊断市场构成了挑战。  

前列腺癌诊断市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息,分析了新兴收入领域、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和前列腺癌诊断市场情况,请联系 Data Bridge Market Research 获取分析师简报,我们的团队将帮助您创建收入影响解决方案以实现您的预​​期目标。

中东和非洲前列腺癌诊断市场前列腺癌诊断市场范围和市场规模

前列腺癌诊断市场根据产品类型、诊断类型、年龄组、类型、阶段、样本类型、最终用户和分销渠道分为八个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略,并确定您的核心应用领域和目标市场的差异。

  • 根据产品类型,前列腺癌诊断市场分为仪器、试剂和耗材以及配件。2021 年,试剂和耗材部分在前列腺癌诊断市场中占据主导地位,因为它包括 PSA 检测产品,这是建议用于初步检测的主要检测。
  • 根据诊断类型,前列腺癌诊断市场分为初步筛查测试和确认测试。2021 年,初步筛查测试部分在前列腺癌诊断市场中占据主导地位,因为初步测试的数量远远超过确认测试的数量。  
  • 根据年龄组,前列腺癌诊断市场分为成人、儿童和老年。2021 年,老年病学在前列腺癌诊断市场中占据主导地位,因为约 60% 的病例是在 65 岁以上的男性中诊断出来的。
  • 根据类型,前列腺癌诊断市场分为前列腺腺癌、小细胞癌和其他。2021 年,前列腺腺癌细分市场在前列腺癌诊断市场中占据主导地位,因为超过 95% 的前列腺癌都是在前列腺腺细胞和前列腺系中发展的腺癌。
  • 根据分期,前列腺癌诊断市场分为局限性前列腺癌、复发性/晚期前列腺癌和去势抵抗性前列腺癌(转移性和非转移性)。2021 年,局限性前列腺癌占据前列腺癌诊断市场的主导地位,因为大约 80% 至 85% 的前列腺癌是在局部或区域阶段发现的,即 I、II 和 III 期。
  • 根据样本类型,前列腺癌诊断市场分为血液、组织、尿液和其他。2021 年,血液部分将主导前列腺癌诊断市场,因为血液是最常见的初步测试(即 PSA 测试)的主要样本,而且由于血液容易获得,血液样本采集程序不太复杂,不需要太多时间,预计这将主导前列腺癌诊断市场。  
  • 根据最终用户,前列腺癌诊断市场细分为独立诊断实验室、医院、癌症研究机构、诊所、门诊手术中心等。2021 年,独立诊断实验室细分市场在前列腺癌诊断市场占据主导地位,因为该细分市场专门从事各种前列腺癌诊断。
  • 根据分销渠道,前列腺癌诊断市场分为直接招标和零售。2021 年,直接招标部分在前列腺癌诊断市场占据主导地位,因为它们是医疗机构和诊断实验室采购试剂、耗材、设备和配件的主要来源。

前列腺癌诊断市场国家层面分析

对前列腺癌诊断市场进行分析,并按上述国家、产品类型、诊断类型、年龄组、类型、阶段、样本类型、最终用户和分销渠道提供市场规模信息。

前列腺癌诊断市场报告涵盖的国家包括南非、沙特阿拉伯、阿联酋、埃及、以色列和中东及非洲其他地区。

由于人们对前列腺癌诊断产品的关注度不断提高以及认识不断提高,预计南非在 2021 年至 2028 年的预测期内将实现增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外,在提供国家数据的预测分析时,还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战、销售渠道的影响。  

制造商的战略举措为前列腺癌诊断市场参与者创造新机遇 

前列腺癌诊断市场还为您提供了每个国家前列腺癌诊断产品销售增长、前列腺癌诊断技术进步的影响以及监管环境变化及其对前列腺癌诊断市场的支持的详细市场分析。数据涵盖 2010 年至 2019 年的历史时期。 

竞争格局和前​​列腺癌诊断市场份额分析

前列腺癌诊断市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对前列腺癌诊断市场的关注有关。  

前列腺癌诊断市场的主要公司包括 F. Hoffmann-La Roche Ltd、ACON Laboratories, Inc.、HUMASIS、Teco Diagnostics、Hologic Inc.、Accuquik Test Kits、MDxHealthcare、Abbott、Siemens Healthcare GmbH、OPKO Health Inc.、Myraid Genetics, Inc.、DiaSorin SpA、Beckman Coulter, Inc.(Danaher 的子公司)、Genomic Health, Inc.(Exact Sciences Corporation 的子公司)、bioMérieux SA、Metamark Genetics, Inc.、Prostatype Genomics、Fujirebio、Proteomedix、Eurolyser Diagnostica GmbH 以及其他国内公司。DBMR 分析师了解竞争优势,并为每个竞争对手分别提供竞争分析。

全球各地的公司也推出了许多产品并达成了多项协议,这也加速了前列腺癌诊断市场的发展。

例如,  

  • 2021 年 1 月,Hologic Inc. 宣布已同意以 6400 万美元收购 SOMATEX, Inc.。该公司是癌症生物标志物的提供商。完成收购后,Hologic Inc. 将在全球肿瘤生物标志物领域取得领先地位,扩大公司针对癌症患者的产品组合,并增加公司未来的销售额和收入。
  • 2020年8月,HUMASIS宣布,在去年11月经过专业评估机构的技术评估后,已于上个月通过了韩国证券交易所的上市初步审查,并将很快获得在韩国证券交易所上市的批准。这对公司来说是一项成就,并将推动公司未来的业务扩展和业务战略。

市场参与者的合作、合资和其他策略正在增强前列腺癌诊断市场的公司市场,这也为组织改善其在前列腺癌诊断市场的供应提供了好处。   

 

 


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USERS COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 EPIDEMIOLOGY

5 COMPARATIVE ANALYSIS WITH PARENT MARKET

6 REGULATORY FRAMEWORK: MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET

6.1 REGULATORY SCENARIO IN THE U.S.

6.2 REGULATORY SCENARIO IN EUROPEAN UNION

6.3 REGULATORY SCENARIO IN JAPAN

6.4 REGULATORY SCENARIO IN CHINA

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE OF PROSTATE CANCER

7.1.2 INCREASE RESEARCH & DEVELOPMENT IN PROSTATE CANCER DIAGNOSTIC

7.1.3 INCREASE IN GERIATRIC POPULATION

7.1.4 LAUNCH OF NEW PRODUCTS FOR PROSTATE CANCER DIAGNOSTIC

7.1.5 DISEASE CAUSING PROSTATE CANCER

7.2 RESTRAINTS

7.2.1 CONTROVERSY RELATED TO PSA TESTING

7.2.2 HIGH COST OF DIAGNOSTICS PROCEDURE

7.2.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS

7.3 OPPORTUNITIES

7.3.1 RISING INVESTMENT AND FUNDING BY EMERGING PLAYERS

7.3.2 REIMBURSEMENT POLICY FOR PROSTATE CANCER DIAGNOSIS

7.3.3 GOVERNMENT INITIATIVES TOWARDS CANCER DIAGNOSTICS

7.3.4 RISING SURVIVAL RATE DUE TO EARLY DIAGNOSIS OF PROSTATE CANCER

7.4 CHALLENGES

7.4.1 STRINGENT REGULATORY REQUIREMENT FOR DIAGNOSTIC PRODUCTS

7.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTICS TESTS

7.4.3 INACCURATE DIAGNOSIS RESULTS

8 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET

8.1 IMPACT ON PRICE

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY CHAIN

8.4 STRATEGIC DECISION BY MANUFACTURERS MADE DURING COVID-19 PANDEMIC

8.5 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19

8.6 CONCLUSION

9 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE

9.1 OVERVIEW

9.2 REAGENTS & CONSUMABLES

9.3 INSTRUMENTS

9.4 ACCESSORIES

10 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE

10.1 OVERVIEW

10.2 PRELIMINARY SCREENING TESTS

10.2.1 PROSTATE-SPECIFIC ANTIGEN (PSA) TEST

10.2.2 DIGITAL RECTAL EXAM (DRE) TEST

10.3 CONFIRMATORY TESTS

10.3.1 PCA3 TEST

10.3.2 BIOPSY

10.3.3 IMAGING TESTS

10.3.3.1 ULTRASOUND

10.3.3.2 MAGNETIC RESONANCE IMAGING (MRI)

10.3.3.2.1 MULTIPARAMETRIC MRI

10.3.3.2.2 MRI FUSION-GUIDED PROSTATE BIOPSY

10.3.3.3 CT SCAN

10.3.3.4 BONE SCAN

10.3.3.5 PET/CT SCAN

10.3.4 BIOMARKER

10.3.4.1 RNA BIOMARKERS

10.3.4.2 DNA BIOMARKERS

10.3.4.3 PROTEIN BIOMARKERS

11 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE

11.1 OVERVIEW

11.2 PROSTATIC ADENOCARCINOMA

11.3 SMALL CELL CARCINOMA

11.4 OTHERS

12 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP

12.1 OVERVIEW

12.2 GERIATRICS

12.3 ADULT

12.4 PEDIATRIC

13 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE

13.1 OVERVIEW

13.2 LOCALIZED PROSTATE CANCER

13.3 RECURRENT/ADVANCED PROSTATE CANCER

13.4 CASTRATION-RESISTANT PROSTATE CANCER (METASTATIC AND NON-METASTATIC)

14 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE

14.1 OVERVIEW

14.2 BLOOD

14.3 TISSUE

14.4 URINE

14.5 OTHERS

15 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS

15.1 OVERVIEW

15.2 INDEPENDENT DIAGNOSTIC LABORATORIES

15.3 HOSPITALS

15.4 CLINICS

15.5 AMBULATORY SURGICAL CENTERS

15.6 CANCER RESEARCH INSTITUTES

15.7 OTHERS

16 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 DIRECT TENDER

16.3 RETAIL SALES

17 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY

17.1 MIDDLE EAST & AFRICA

17.1.1 SOUTH AFRICA

17.1.2 SAUDI ARABIA

17.1.3 UAE

17.1.4 ISRAEL

17.1.5 EGYPT

17.1.6 REST OF MIDDLE EAST & AFRICA

18 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

19 SWOT

20 COMPANY PROFILE

20.1 F. HOFFMANN-LA ROCHE LTD

20.1.1 COMPANY SNAPSHOT

20.1.2 REVENUE ANALYSIS

20.1.3 COMPANY SHARE ANALYSIS

20.1.4 PRODUCT PORTFOLI0

20.1.5 RECENT DEVELOPMENTS

20.2 ABBOTT

20.2.1 COMPANY SNAPSHOT

20.2.2 REVENUE ANALYSIS

20.2.3 COMPANY SHARE ANALYSIS

20.2.4 PRODUCT PORTFOLIO

20.2.5 RECENT DEVELOPMENTS

20.3 SIEMENS HEALTHCARE GMBH

20.3.1 COMPANY SNAPSHOT

20.3.2 REVENUE ANALYSIS

20.3.3 COMPANY SHARE ANALYSIS

20.3.4 PRODUCT PORTFOLIO

20.3.5 RECENT DEVELOPMENTS

20.4 OPKO HEALTH INC.

20.4.1 COMPANY SNAPSHOT

20.4.2 REVENUE ANALYSIS

20.4.3 COMPANY SHARE ANALYSIS

20.4.4 PRODUCT PORTFOLIO

20.4.5 RECENT DEVELOPMENTS

20.5 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER)

20.5.1 COMPANY SNAPSHOT

20.5.2 REVENUE ANALYSIS

20.5.3 COMPANY SHARE ANALYSIS

20.5.4 PRODUCT PORTFOLIO

20.5.5 RECENT DEVELOPMENTS

20.6 ACCUQUIK TEST KITS

20.6.1 COMPANY SNAPSHOT

20.6.2 PRODUCT PORTFOLIO

20.6.3 RECENT DEVELOPMENT

20.7 ACON LABORATORIES INC.

20.7.1 COMPANY SNAPSHOT

20.7.2 PRODUCT PORTFOLIO

20.7.3 RECENT DEVELOPMENTS

20.8 BIOMERIEUX SA

20.8.1 COMPANY SNAPSHOT

20.8.2 REVENUE ANALYSIS

20.8.3 PRODUCT PORTFOLIO

20.8.4 RECENT DEVELOPMENT

20.9 DIASORIN S.P.A

20.9.1 COMPANY SNAPSHOT

20.9.2 REVENUE ANALYSIS

20.9.3 PRODUCT PORTFOLI0

20.9.4 RECENT DEVELOPMENTS

20.1 EUROLYSER DIAGNOSTICA GMBH

20.10.1 COMPANY SNAPSHOT

20.10.2 PRODUCT PORTFOLIO

20.10.3 RECENT DEVELOPMENT

20.11 FUJIREBIO

20.11.1 COMPANY SNAPSHOT

20.11.2 PRODUCT PORTFOLI

20.11.3 RECENT DEVELOPMENTS

20.12 GENOMIC HEALTH, INC., (A SUBSIDIARY OF EXACT SCIENCES CORPORATION)

20.12.1 COMPANY SNAPSHOT

20.12.2 REVENUE ANALYSIS

20.12.3 PRODUCT PORTFOLIO

20.12.4 RECENT DEVELOPMENTS

20.13 HOLOGIC, INC.

20.13.1 COMPANY SNAPSHOT

20.13.2 REVENUE ANALYSIS

20.13.3 PRODUCT PORTFOLIO

20.13.4 RECENT DEVELOPMENTS

20.14 HUMASIS

20.14.1 COMPANY SNAPSHOT

20.14.2 PRODUCT PORTFOLIO

20.14.3 RECENT DEVELOPMENTS

20.15 MDXHEALTHCARE

20.15.1 COMPANY SNAPSHOT

20.15.2 REVENUE ANALYSIS

20.15.3 PRODUCT PORTFOLIO

20.15.4 RECENT DEVELOPMENTS

20.16 METAMARK GENETICS, INC.

20.16.1 COMPANY SNAPSHOT

20.16.2 PRODUCT PORTFOLI0

20.16.3 RECENT DEVELOPMENTS

20.17 MYRAID GENETICS, INC.

20.17.1 COMPANY SNAPSHOT

20.17.2 REVENUE ANALYSIS

20.17.3 PRODUCT PORTFOLIO

20.17.4 RECENT DEVELOPMENTS

20.18 PROSTATYPE GENOMICS

20.18.1 COMPANY SNAPSHOT

20.18.2 REVENUE ANALYSIS

20.18.3 PRODUCT PORTFOLIO

20.18.4 RECENT DEVELOPMENTS

20.19 PROTEOMEDIX

20.19.1 COMPANY SNAPSHOT

20.19.2 PRODUCT PORTFOLIO

20.19.3 RECENT DEVELOPMENTS

20.2 TECO DIAGNOSTICS

20.20.1 COMPANY SNAPSHOT

20.20.2 PRODUCT PORTFOLIO

20.20.3 RECENT DEVELOPMENT

21 QUESTIONNAIRE

22 RELATED REPORTS

表格列表

LIST OF TABLES

TABLE 1 CATEGORIZATION UNDER THE CLINICAL LABORATORY IMPROVEMENT AMENDMENTS (CLIA '88) OF 1988

TABLE 2 AGE AND PROBABILITY OF DEVELOPING PROSTATE CANCER

TABLE 3 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 2019-2028 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 2019-2028 (UNITS)

TABLE 5 MIDDLE EAST AND AFRICA REAGENTS & CONSUMABLES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA INSTRUMENTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA ACCESSORIES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA CONFIRMATORY TESTSIN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA PROSTATIC ADENOCARCINOMAS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION

TABLE 13 MIDDLE EAST AND AFRICA SMALL CELL CARCINOMA IN PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA OTHERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP 2019-2028 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA GERIATRICS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA SEVERE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA SEVERE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA LOCALIZED PROSTATE CANCER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA RECURRENT/ADVANCED PROSTATE CANCER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA CASTRATION-RESISTANT PROSTATE CANCER (METASTATIC AND NON-METASTATIC) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA BLOOD IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA TISSUE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA URINE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA OTHERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA INDEPENDENT DIAGNOSTIC LABORATORIES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA HOSPITALS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA CLINICS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA CANCER RESEARCH INSTITUTES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA OTHERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA DIRECT TENDER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA HOSPITALS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)

TABLE 41 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 46 MIDDLE EAST & AFRICA BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 47 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)

TABLE 48 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 49 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 52 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 53 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 54 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)

TABLE 55 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 56 SOUTH AFRICA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 57 SOUTH AFRICA CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 58 SOUTH AFRICA IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 59 SOUTH AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 60 SOUTH AFRICA BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 61 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)

TABLE 62 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 63 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 64 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 65 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 66 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 67 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 68 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)

TABLE 69 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 70 SAUDI ARABIA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 71 SAUDI ARABIA CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 72 SAUDI ARABIA IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 73 SAUDI ARABIA MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 74 SAUDI ARABIA BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 75 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)

TABLE 76 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 77 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 78 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 79 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 80 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 81 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 82 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)

TABLE 83 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 84 UAE PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 85 UAE CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 86 UAE IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 87 UAE MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 88 UAE BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 89 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)

TABLE 90 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 91 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 92 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 93 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 94 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 95 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 96 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)

TABLE 97 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 98 ISRAEL PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 99 ISRAEL CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 100 ISRAEL IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 101 ISRAEL MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 102 ISRAEL BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 103 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)

TABLE 104 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 105 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 106 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 107 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 108 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 109 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 110 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)

TABLE 111 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 112 EGYPT PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 113 EGYPT CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 114 EGYPT IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 115 EGYPT MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 116 EGYPT BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 117 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)

TABLE 118 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 119 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 120 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 121 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 122 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 123 REST OF MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

 

图片列表

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET : DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: MULTIVARIATE MODELLING

FIGURE 7 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: MARKET END USERS COVERAGE GRID

FIGURE 10 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF PROSTATE CANCER AND INCREASED RESEARCH & DEVELOPMENT IN PROSTATE CANCER DIAGNOSTICS ARE DRIVING THE MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET IN 2021 & 2028

FIGURE 14 REGULATORY FRAMEWORK FOR APPROVAL PROCESS IN CHINA

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET

FIGURE 16 ESTIMATED INCIDENCE CASES OF PROSTATE CANCER, ALL AGES

FIGURE 17 GERIATRIC POPULATION IN THE EUROPEAN REGION

FIGURE 18 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2020

FIGURE 19 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2020-2028 (USD MILLION)

FIGURE 20 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2021-2028)

FIGURE 21 PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 22 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE, 2020

FIGURE 23 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE 2020-2028 (USD MILLION)

FIGURE 24 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE, CAGR (2021-2028)

FIGURE 25 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE, LIFELINE CURVE

FIGURE 26 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, 2020

FIGURE 27 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, 2020-2028 (USD MILLION)

FIGURE 28 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2020-2028)

FIGURE 29 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 30 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2020

FIGURE 31 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP , 2020-2028 (USD MILLION)

FIGURE 32 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2021-2028)

FIGURE 33 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 34 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, 2020

FIGURE 35 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, 2020-2028 (USD MILLION)

FIGURE 36 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, CAGR (2021-2028)

FIGURE 37 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, LIFELINE CURVE

FIGURE 38 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2020

FIGURE 39 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2020-2028 (USD MILLION)

FIGURE 40 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, CAGR (2021-2028)

FIGURE 41 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, LIFELINE CURVE

FIGURE 42 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, 2020

FIGURE 43 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, 2020-2028 (USD MILLION)

FIGURE 44 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, CAGR (2021-2028)

FIGURE 45 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, LIFELINE CURVE

FIGURE 46 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 47 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 48 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 49 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION, LIFELINE CURVE

FIGURE 50 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: SNAPSHOT (2020)

FIGURE 51 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020)

FIGURE 52 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)

FIGURE 53 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)

FIGURE 54 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2021-2028)

FIGURE 55 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2020 (%)

 

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Middle East and Africa Prostate Cancer Diagnostics Market is projected to grow at a CAGR of 12.9% during the forecast period by 2028.
The future market value of the Middle East and Africa Prostate Cancer Diagnostics Market is expected to reach USD 320.40 million by 2028.
The major players in the Middle East and Africa Prostate Cancer Diagnostics Market are F. Hoffmann-La Roche Ltd, ACON Laboratories, Inc., HUMASIS, Teco Diagnostics, Hologic Inc., Accuquik Test Kits, MDxHealthcare, Abbott, Siemens Healthcare GmbH, OPKO Health Inc., etc.
The countries covered in the Middle East and Africa Prostate Cancer Diagnostics Market are South Africa, Saudi Arabia, UAE, Egypt, Israel & Rest of Middle East and Africa.